Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 8
- Registration Number
- NCT04179396
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Urology Associates, P.C., Nashville, Tennessee, United States
🇺🇸Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 100
- Registration Number
- NCT04175431
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT04087174
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT04071262
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 268
- Registration Number
- NCT04056754
- Locations
- 🇨🇳
TongJi medical college of HuaZhong University of Science & Technology Affiliated TongJi Hospital, Wuhan, Hubei, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 979
- Registration Number
- NCT04034095
- Locations
- 🇯🇵
Akita University Hospital, Akita, Japan
🇯🇵Juntendo University Hospital, Bunkyo Ku, Japan
🇯🇵Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3
- Registration Number
- NCT03999515
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
- Conditions
- Interventions
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 22
- Registration Number
- NCT03934840
- Locations
- 🇺🇸
Thomas Jeferson University, Philadelphia, Pennsylvania, United States
🇺🇸Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03902951
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 346
- Registration Number
- NCT03896984
- Locations
- 🇺🇸
US Flatiron prostate cancer database, Whippany, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.